Research on Investigational New Drugs

  • Mary Kay Ryan
  • Lawrence Gold
  • Bruce Kay


There is a growing national concern with drugs in our society, including the ways in which drugs are developed, tested, and marketed by pharmaceutical companies, the extent and effectiveness of the Food and Drug Administration’s (FDA) control, and the possibility of unforeseen long-range harmful effects to individuals taking certain drugs.


Package Insert Investigational Drug American Hospital Association Therapeutics Committee American Enterprise Institute 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arbit, H. M., 1978, Regulatory aspects of investigational new drugs, Am. J. Hosp. Pharm. 35:81–85.Google Scholar
  2. Donehew, G. and Schaumberg, J. P., 1979, The pharmacist’s role as a member of the institutional review board, Hosp. Pharm. 14:509–519.Google Scholar
  3. Hassan, W. E., Jr., 1965, Hospital Pharmacy, pp. 75–87, Lea and Febiger, Philadelphia.Google Scholar
  4. Herbst, A. L., Ulfelder, H., and Poskanzer, D., 1971, Adenocarcinoma of the vagina, association of maternal stilbesterol therapy with tumor appearance in young women, N. Engl. J. Med. 284(16):878–881.CrossRefGoogle Scholar
  5. Hiranaka, P. K., and Gallelli, J. F., 1979, Investigational drugs in the hospital, in: Handbook of Institutional Pharmacy Practice (M. C. Smith and T. R. Brown, eds.) pp. 382–397, Williams & Wilkins, Baltimore.Google Scholar
  6. Kaganov, A. L., 1980, Medical device development: Innovation versus regulation, Ann. Thora. Surg. 29:331–335.CrossRefGoogle Scholar
  7. Kelsey, F. O., 1965, Problems raised for the FDA by the occurrence of thalidamide embryopathy in Germany, Am. J. Publ. Health 55:703–707.CrossRefGoogle Scholar
  8. Kleinman, L. M., and Tangera, J. A., 1974, Involvement of the hospital pharmacist in single and double-blind studies, Am. J. Hosp. Pharm. 31:979–981.Google Scholar
  9. Kleinman, L. M., Tangera, J. A., and Gallelli, J. F., 1974, Control of investigational drugs in research hospitals, Am. J. Hosp. Pharm. 31:368–371.Google Scholar
  10. Lanton, R. L., 1965, A community-wide project for the collection of adverse drug reaction reports, Am. J. Hosp. Pharm. 22(8):470.Google Scholar
  11. Lasagna, L., 1968, General considerations concerning untoward effects of drugs in man, Proceedings of the Third International Pharmacological Meeting Sao Paulo, Brazil, Vol. 3 (M. Rocha e Silva, ed.), p. 84, Pergamon Press, Oxford.Google Scholar
  12. Lasagna, L., and Wardell, W., 1975, The rate of new drug discovery, in: Drug Development and Marketing (R. B. Helms, ed.), p. 157, American Enterprise Institute for Public Policy Research.Google Scholar
  13. Luy, M. L., 1976, Package Insert Roulette: The “Catch 23” of prescribing, Mod. Med. (Chicago) 1976:20–23.Google Scholar
  14. Mandl, F. L., Greenberg, R. B., 1976, Legal implications of preparing and dispensing drugs under conditions not in a product’s official labeling, Am. J. Hosp. Pharm. 33:814–816.Google Scholar
  15. Stephen, S. P., and McKinley, J. D., 1974, Investigational drug information in a cancer research hospital, Am. J. Hosp. Pharm. 31:372–374.Google Scholar
  16. Physicians’ Desk Reference, published annually by Medical Economics, Oradell, New Jersey.Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Mary Kay Ryan
    • 1
  • Lawrence Gold
    • 1
  • Bruce Kay
    • 1
  1. 1.Long Island Jewish-Hillside Medical CenterNew Hyde ParkUSA

Personalised recommendations